Chimeric virus-like particles (VLPs) designed from shrimp nodavirus (MrNV) capsid protein specifically target EGFR-positive human colorectal cancer cells

Grataitong, Khwanthana; Huault, Sébastien; Chotwiwatthanakun, Charoonroj; Jariyapong, Pitchanee; Thongsum, Orawan; Chawiwithaya, Chidchanok; Chakrabandhu, Krittalak; Hueber, Anne-Odile; Weerachatyanukul, Wattana

doi:10.1038/s41598-021-95891-x

Cited by 10 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to note that VLPs may cause side effects, such as injection site pain and swelling [302]. Given these factors, it is unsurprising that VLPs have become an attractive platform for vaccine design over the past two decades [69,301,[306][307][308][309][310].…”

Section: Virus-like Particlesmentioning

confidence: 99%

The quest for nanoparticle-powered vaccines in cancer immunotherapy

Sun,

Zhao,

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Despite recent advancements in cancer treatment, this disease still poses a serious threat to public health. Vaccines play an important role in preventing illness by preparing the body's adaptive and innate immune responses to combat diseases. As our understanding of malignancies and their connection to the immune system improves, there has been a growing interest in priming the immune system to fight malignancies more effectively and comprehensively. One promising approach involves utilizing nanoparticle systems for antigen delivery, which has been shown to potentiate immune responses as vaccines and/or adjuvants. In this review, we comprehensively summarized the immunological mechanisms of cancer vaccines while focusing specifically on the recent applications of various types of nanoparticles in the field of cancer immunotherapy. By exploring these recent breakthroughs, we hope to identify significant challenges and obstacles in making nanoparticle-based vaccines and adjuvants feasible for clinical application. This review serves to assess recent breakthroughs in nanoparticle-based cancer vaccinations and shed light on their prospects and potential barriers. By doing so, we aim to inspire future immunotherapies for cancer that harness the potential of nanotechnology to deliver more effective and targeted treatments. Graphical abstract

show abstract

Section: Virus-like Particlesmentioning

confidence: 99%

The quest for nanoparticle-powered vaccines in cancer immunotherapy

Sun,

Zhao,

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Among other reasons, this is due to the fact that they have a lipid envelope, which is extremely sensitive to the thermal conditions and shear forces generated during the purification stage [ 107 ]. For this reason, VLPs without the envelope are gaining more attention in therapy, where their use has been reported in research for the treatment of colorectal cancer and CNS-related diseases, among others [ 19 , 101 , 108 , 109 ].…”

Section: Virus-like Particles In the Treatment Of Central Nervous Sys...mentioning

confidence: 99%

Virus-Based Biological Systems as Next-Generation Carriers for the Therapy of Central Nervous System Diseases

Nowak,

Madej,

Secemska

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Central nervous system (CNS) diseases are currently a major challenge in medicine. One reason is the presence of the blood–brain barrier, which is a significant limitation for currently used medicinal substances that are characterized by a high molecular weight and a short half-life. Despite the application of nanotechnology, there is still the problem of targeting and the occurrence of systemic toxicity. Viral vectors and virus-like particles (VLPs) may provide a promising solution to these challenges. Their small size, biocompatibility, ability to carry medicinal substances, and specific targeting of neural cells make them useful in research when formulating a new generation of biological carriers. Additionally, the possibility of genetic modification has the potential for gene therapy. Among the most promising viral vectors are adeno-associated viruses, adenoviruses, and retroviruses. This is due to their natural tropism to neural cells, as well as the possibility of genetic and surface modification. Moreover, VLPs that are devoid of infectious genetic material in favor of increasing capacity are also leading the way for research on new drug delivery systems. The aim of this study is to review the most recent reports on the use of viral vectors and VLPs in the treatment of selected CNS diseases.

show abstract

“…They are mostly derived by genetic manipulations, where their application in this instance depends on peculiar advantages which are lacking in the commonly used vectors. For example, engineered virus-like particles designed from capsid proteins of shrimp nodavirus armed with EGFR-specific (GE11) peptide exhibited antigen-dependent in vitro transduction in EGFR positive cell lines but not in EGFR-negative control cells [ 63 ]. Another promising gene delivery virus is the herpes simplex viruses (HSV).…”

Section: Classification Of Ddsmentioning

confidence: 99%

Technological advances in the use of viral and non-viral vectors for delivering genetic and non-genetic cargos for cancer therapy

Dogbey,

Torres,

Fajemisin

et al. 2023

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

The burden of cancer is increasing globally. Several challenges facing its mainstream treatment approaches have formed the basis for the development of targeted delivery systems to carry and distribute anti-cancer payloads to their defined targets. This site-specific delivery of drug molecules and gene payloads to selectively target druggable biomarkers aimed at inducing cell death while sparing normal cells is the principal goal for cancer therapy. An important advantage of a delivery vector either viral or non-viral is the cumulative ability to penetrate the haphazardly arranged and immunosuppressive tumour microenvironment of solid tumours and or withstand antibody-mediated immune response. Biotechnological approaches incorporating rational protein engineering for the development of targeted delivery systems which may serve as vehicles for packaging and distribution of anti-cancer agents to selectively target and kill cancer cells are highly desired. Over the years, these chemically and genetically modified delivery systems have aimed at distribution and selective accumulation of drug molecules at receptor sites resulting in constant maintenance of high drug bioavailability for effective anti-tumour activity. In this review, we highlighted the state-of-the art viral and non-viral drug and gene delivery systems and those under developments focusing on cancer therapy. Graphical Abstract

show abstract

Chimeric virus-like particles (VLPs) designed from shrimp nodavirus (MrNV) capsid protein specifically target EGFR-positive human colorectal cancer cells

Cited by 10 publications

References 43 publications

The quest for nanoparticle-powered vaccines in cancer immunotherapy

The quest for nanoparticle-powered vaccines in cancer immunotherapy

Virus-Based Biological Systems as Next-Generation Carriers for the Therapy of Central Nervous System Diseases

Technological advances in the use of viral and non-viral vectors for delivering genetic and non-genetic cargos for cancer therapy

Contact Info

Product

Resources

About